David Rodman is the founder of Mineralys Therapeutics. Mineralys Therapeutics has raised $328M in total funding. Latest round: Series A.
David Rodman is the Chief Medical Officer (CMO) of Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for hypertension. He joined the company shortly after its Series A funding round in April 2021. As CMO, Rodman oversees the advancement of MLS-101 through Phase 2 and pivotal trial development.
Full founder directory · Investor directory · Company funding database · Fundraising library